EA016039B1 - Способы ухода за лактирующими животными и фармацевтические композиции, используемые для их осуществления - Google Patents
Способы ухода за лактирующими животными и фармацевтические композиции, используемые для их осуществления Download PDFInfo
- Publication number
- EA016039B1 EA016039B1 EA200702401A EA200702401A EA016039B1 EA 016039 B1 EA016039 B1 EA 016039B1 EA 200702401 A EA200702401 A EA 200702401A EA 200702401 A EA200702401 A EA 200702401A EA 016039 B1 EA016039 B1 EA 016039B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- casein
- peptide
- milk
- isolated
- amino acid
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 108
- 238000000034 method Methods 0.000 title claims abstract description 99
- 241001465754 Metazoa Species 0.000 title claims abstract description 96
- 244000144972 livestock Species 0.000 title claims abstract description 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 232
- 239000005018 casein Substances 0.000 claims abstract description 208
- 235000013336 milk Nutrition 0.000 claims abstract description 206
- 239000008267 milk Substances 0.000 claims abstract description 206
- 210000004080 milk Anatomy 0.000 claims abstract description 206
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims abstract description 181
- 235000021240 caseins Nutrition 0.000 claims abstract description 181
- 239000000203 mixture Substances 0.000 claims abstract description 56
- 239000000693 micelle Substances 0.000 claims abstract description 25
- 230000001965 increasing effect Effects 0.000 claims abstract description 18
- 102000011632 Caseins Human genes 0.000 claims description 205
- 108010076119 Caseins Proteins 0.000 claims description 205
- 241000283690 Bos taurus Species 0.000 claims description 198
- 238000011282 treatment Methods 0.000 claims description 136
- 230000006651 lactation Effects 0.000 claims description 86
- 208000004396 mastitis Diseases 0.000 claims description 83
- 108010001441 Phosphopeptides Proteins 0.000 claims description 80
- 210000005075 mammary gland Anatomy 0.000 claims description 69
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 59
- 208000015181 infectious disease Diseases 0.000 claims description 52
- 210000004907 gland Anatomy 0.000 claims description 46
- 239000012634 fragment Substances 0.000 claims description 30
- 238000004519 manufacturing process Methods 0.000 claims description 29
- 150000001413 amino acids Chemical class 0.000 claims description 28
- 210000004027 cell Anatomy 0.000 claims description 25
- 210000002445 nipple Anatomy 0.000 claims description 24
- 235000021247 β-casein Nutrition 0.000 claims description 22
- 230000004936 stimulating effect Effects 0.000 claims description 15
- 241000283707 Capra Species 0.000 claims description 12
- 230000002829 reductive effect Effects 0.000 claims description 9
- 230000009467 reduction Effects 0.000 claims description 8
- 241001494479 Pecora Species 0.000 claims description 7
- 239000003242 anti bacterial agent Substances 0.000 claims description 7
- 229940088710 antibiotic agent Drugs 0.000 claims description 6
- 210000001082 somatic cell Anatomy 0.000 claims description 6
- 229960005486 vaccine Drugs 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 5
- 235000002198 Annona diversifolia Nutrition 0.000 claims description 4
- 241000282326 Felis catus Species 0.000 claims description 4
- 239000002955 immunomodulating agent Substances 0.000 claims description 4
- 229940121354 immunomodulator Drugs 0.000 claims description 4
- 230000003637 steroidlike Effects 0.000 claims description 4
- 241000283074 Equus asinus Species 0.000 claims description 3
- 239000004599 antimicrobial Substances 0.000 claims description 3
- 239000003899 bactericide agent Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000008176 lyophilized powder Substances 0.000 claims description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 241000282836 Camelus dromedarius Species 0.000 claims description 2
- 241000283073 Equus caballus Species 0.000 claims description 2
- 241000282842 Lama glama Species 0.000 claims description 2
- 241000282898 Sus scrofa Species 0.000 claims description 2
- 230000002906 microbiologic effect Effects 0.000 claims description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- 241000009328 Perro Species 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 83
- 239000008174 sterile solution Substances 0.000 abstract description 7
- 230000032696 parturition Effects 0.000 abstract description 4
- 230000003247 decreasing effect Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 45
- 210000000481 breast Anatomy 0.000 description 39
- 239000000243 solution Substances 0.000 description 38
- 235000001014 amino acid Nutrition 0.000 description 31
- 229940024606 amino acid Drugs 0.000 description 31
- 238000012360 testing method Methods 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 23
- 201000010099 disease Diseases 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 244000144980 herd Species 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 22
- 244000005700 microbiome Species 0.000 description 19
- 230000003115 biocidal effect Effects 0.000 description 18
- 230000007423 decrease Effects 0.000 description 18
- 235000013365 dairy product Nutrition 0.000 description 17
- 230000008569 process Effects 0.000 description 16
- 238000002560 therapeutic procedure Methods 0.000 description 16
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 125000000539 amino acid group Chemical group 0.000 description 13
- 238000001914 filtration Methods 0.000 description 12
- 244000052769 pathogen Species 0.000 description 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- 230000035606 childbirth Effects 0.000 description 10
- 235000013305 food Nutrition 0.000 description 10
- 230000000638 stimulation Effects 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 238000005755 formation reaction Methods 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 8
- 230000000721 bacterilogical effect Effects 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 238000006722 reduction reaction Methods 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 238000011109 contamination Methods 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- 239000011261 inert gas Substances 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 230000002411 adverse Effects 0.000 description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 230000007717 exclusion Effects 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000035935 pregnancy Effects 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 230000009897 systematic effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 208000035143 Bacterial infection Diseases 0.000 description 4
- 108010088842 Fibrinolysin Proteins 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- -1 p-toluenesulfonyl groups Chemical group 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 241000282832 Camelidae Species 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 108010065152 Coagulase Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 241001442654 Percnon planissimum Species 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229940066779 peptones Drugs 0.000 description 3
- 229940012957 plasmin Drugs 0.000 description 3
- 238000009117 preventive therapy Methods 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 2
- BLCJBICVQSYOIF-UHFFFAOYSA-N 2,2-diaminobutanoic acid Chemical compound CCC(N)(N)C(O)=O BLCJBICVQSYOIF-UHFFFAOYSA-N 0.000 description 2
- 208000031504 Asymptomatic Infections Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241000282838 Lama Species 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 241000282890 Sus Species 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000003862 amino acid derivatives Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000008452 baby food Nutrition 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 108010006025 bovine growth hormone Proteins 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000003977 dairy farming Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 210000004251 human milk Anatomy 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002766 immunoenhancing effect Effects 0.000 description 2
- 230000002584 immunomodulator Effects 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000011005 laboratory method Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical group OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 235000004400 serine Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 235000021249 α-casein Nutrition 0.000 description 2
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 1
- 241001182632 Akko Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 206010006261 Breast infections Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010006312 Breast swelling Diseases 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010028470 Mycoplasma infections Diseases 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000021129 Postpartum disease Diseases 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- GELXFVQAWNTGPQ-UHFFFAOYSA-N [N].C1=CNC=N1 Chemical compound [N].C1=CNC=N1 GELXFVQAWNTGPQ-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000036981 active tuberculosis Diseases 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229940070021 anabolic steroids Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000001974 anti-anabolic effect Effects 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- 238000007630 basic procedure Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000000069 breast epithelial cell Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000001314 canonical amino-acid group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 244000000015 environmental pathogen Species 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000009408 flooring Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000012248 genetic selection Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical class C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical group 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000010954 inorganic particle Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 208000030175 lameness Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000027739 mammary gland involution Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 235000013384 milk substitute Nutrition 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000011146 organic particle Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000009304 pastoral farming Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000005195 poor health Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 238000011045 prefiltration Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000026777 severe mastitis Diseases 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 235000002374 tyrosine Nutrition 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67629205P | 2005-05-02 | 2005-05-02 | |
| US68869705P | 2005-06-09 | 2005-06-09 | |
| PCT/IL2006/000524 WO2006117784A2 (en) | 2005-05-02 | 2006-05-02 | Pharmaceutical compositions comprising casein derived peptides and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200702401A1 EA200702401A1 (ru) | 2008-08-29 |
| EA016039B1 true EA016039B1 (ru) | 2012-01-30 |
Family
ID=37308387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200702401A EA016039B1 (ru) | 2005-05-02 | 2006-05-02 | Способы ухода за лактирующими животными и фармацевтические композиции, используемые для их осуществления |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7968513B2 (https=) |
| EP (1) | EP1890720B1 (https=) |
| JP (1) | JP5247429B2 (https=) |
| KR (2) | KR20130122979A (https=) |
| CN (1) | CN106421749A (https=) |
| AR (1) | AR059462A1 (https=) |
| AU (1) | AU2006242842B2 (https=) |
| BR (1) | BRPI0611301A2 (https=) |
| CA (1) | CA2607155C (https=) |
| CL (1) | CL2011000039A1 (https=) |
| EA (1) | EA016039B1 (https=) |
| ES (1) | ES2400511T3 (https=) |
| IN (1) | IN2014DN10391A (https=) |
| MX (1) | MX2007013866A (https=) |
| NZ (1) | NZ563936A (https=) |
| PL (1) | PL1890720T3 (https=) |
| UY (1) | UY29515A1 (https=) |
| WO (1) | WO2006117784A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2725841C2 (ru) * | 2013-06-06 | 2020-07-06 | Сева Сантэ Анималь | Композиции и способ контроля инфекций у млекопитающих, не относящихся к человеку, с применением белков острой фазы |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7968513B2 (en) * | 2005-05-02 | 2011-06-28 | Mileutis Ltd. | Pharmaceutical compositions comprising casein derived peptides and methods of use thereof |
| CN102124109B (zh) * | 2008-06-30 | 2013-10-16 | Cho-A制药有限公司 | 猪α-S1-酪蛋白基因，其启动子及其用途 |
| US8133916B1 (en) | 2009-03-10 | 2012-03-13 | Amelgo, LLC | Control of milk production and mammary involution |
| US20110017323A1 (en) * | 2009-07-22 | 2011-01-27 | Ewa Herbst | Method and apparatus for inline testing |
| CN102933223B (zh) * | 2010-04-21 | 2016-03-09 | 米勒尤迪斯公司 | 用于治疗子宫感染的酪蛋白肽 |
| FR2971423B1 (fr) * | 2011-02-15 | 2014-01-10 | Ceva Sante Animale | Composition veterinaire antiprolactinique destinee aux ruminants |
| EP2828281B1 (en) * | 2012-03-19 | 2019-09-18 | Mileutis Ltd. | Peptides for management of lactation |
| WO2018085886A1 (en) * | 2016-11-09 | 2018-05-17 | Charles Sturt University | Livestock supplement and use thereof |
| WO2018108975A1 (en) * | 2016-12-13 | 2018-06-21 | Dsm Ip Assets B.V. | Pufa salt formulations (i) |
| CN108017709B (zh) * | 2017-12-12 | 2020-04-10 | 浙江辉肽生命健康科技有限公司 | 一种生物活性多肽kepmigvnqela及其制备方法和应用 |
| JP2023515120A (ja) * | 2020-02-19 | 2023-04-12 | パーフェクト・デイ・インコーポレイテッド | 低アレルギー性組換え乳タンパク質およびこれを含む組成物 |
| JP2025537820A (ja) * | 2022-11-17 | 2025-11-20 | ミレウティス リミテッド． | 乳房の障害および状態を調節するための組成物および方法 |
| CN121358342A (zh) * | 2023-05-16 | 2026-01-16 | 米勒尤迪斯公司 | 提升的乳质 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6391849B1 (en) * | 1999-11-19 | 2002-05-21 | Agricultural Research Organization, The Volcani Center | Method and pharmaceutical composition for disrupting lactation in a mammary gland and for treating and preventing mastitis |
| US6780844B1 (en) * | 1997-03-13 | 2004-08-24 | The University Of Melbourne | Calcium phosphopeptide complexes |
| US20050220801A1 (en) * | 2001-03-09 | 2005-10-06 | Hajime Otani | Immunopotentiators |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3764670A (en) | 1970-10-28 | 1973-10-09 | Ministry Of Agriculture | Polypeptidic anti-biotic substances derived from casein |
| FR2474829B1 (fr) | 1980-02-01 | 1983-09-09 | Agronomique Inst Nat Rech | Procede de traitement d'une matiere a base de caseine contenant des phosphocaseinates de cations monovalents ou leurs derives, produits obtenus et applications |
| US5405756A (en) | 1982-03-30 | 1995-04-11 | Meiji Seika Kaisha, Ltd. | Transparent acid drink containing acid-soluble casein phosphopeptide |
| US5015628A (en) * | 1986-06-12 | 1991-05-14 | The University Of Melbourne | Anticariogenic phosphopeptides |
| NZ242415A (en) * | 1991-04-19 | 1993-10-26 | Univ Melbourne | Preparation of anticariogenic phosphopeptides from casein |
| US5227154A (en) | 1991-08-22 | 1993-07-13 | The University Of Melbourne | Phosphopeptides for the treatment of dental calculus |
| KR0140248B1 (ko) | 1995-03-23 | 1998-06-15 | 한상기 | 신규한 카제인 포스포펩티드, 그것을 포함하는 카제인 및 그 제조방법 |
| AUPP494798A0 (en) | 1998-07-29 | 1998-08-20 | Pacific Biolink Pty Limited | Protective protein formulation |
| NZ517249A (en) | 1999-08-24 | 2004-09-24 | Meiji Seika Kaisha | Growth promoting and imunpotentiator compositions for mammals using a milk casein phosphopeptide |
| IL134830A0 (en) | 2000-03-01 | 2001-05-20 | Chay 13 Medical Res Group N V | Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them |
| US7666996B2 (en) | 2000-03-01 | 2010-02-23 | Peptera Pharmaceuticals Ltd | Casein derived peptides and uses thereof |
| EA200601575A1 (ru) | 2004-03-01 | 2007-06-29 | Пептера Фармасьютикалс Лтд. | Казеиновые пептиды и их терапевтическое применение |
| US7968513B2 (en) * | 2005-05-02 | 2011-06-28 | Mileutis Ltd. | Pharmaceutical compositions comprising casein derived peptides and methods of use thereof |
-
2006
- 2006-05-02 US US11/913,239 patent/US7968513B2/en active Active
- 2006-05-02 MX MX2007013866A patent/MX2007013866A/es active IP Right Grant
- 2006-05-02 WO PCT/IL2006/000524 patent/WO2006117784A2/en not_active Ceased
- 2006-05-02 UY UY29515A patent/UY29515A1/es not_active Application Discontinuation
- 2006-05-02 JP JP2008509574A patent/JP5247429B2/ja not_active Expired - Lifetime
- 2006-05-02 IN IN10391DEN2014 patent/IN2014DN10391A/en unknown
- 2006-05-02 NZ NZ563936A patent/NZ563936A/en unknown
- 2006-05-02 KR KR1020137025206A patent/KR20130122979A/ko not_active Ceased
- 2006-05-02 EA EA200702401A patent/EA016039B1/ru not_active IP Right Cessation
- 2006-05-02 AU AU2006242842A patent/AU2006242842B2/en active Active
- 2006-05-02 PL PL06728320T patent/PL1890720T3/pl unknown
- 2006-05-02 ES ES06728320T patent/ES2400511T3/es not_active Expired - Lifetime
- 2006-05-02 CA CA2607155A patent/CA2607155C/en not_active Expired - Lifetime
- 2006-05-02 CN CN201610544021.9A patent/CN106421749A/zh active Pending
- 2006-05-02 BR BRPI0611301-0A patent/BRPI0611301A2/pt not_active Application Discontinuation
- 2006-05-02 EP EP06728320A patent/EP1890720B1/en not_active Expired - Lifetime
- 2006-05-15 AR ARP060101766A patent/AR059462A1/es not_active Application Discontinuation
-
2007
- 2007-12-03 KR KR1020077028185A patent/KR101340676B1/ko not_active Expired - Lifetime
-
2011
- 2011-01-07 CL CL2011000039A patent/CL2011000039A1/es unknown
- 2011-05-13 US US13/107,331 patent/US8338363B2/en not_active Expired - Lifetime
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6780844B1 (en) * | 1997-03-13 | 2004-08-24 | The University Of Melbourne | Calcium phosphopeptide complexes |
| US6391849B1 (en) * | 1999-11-19 | 2002-05-21 | Agricultural Research Organization, The Volcani Center | Method and pharmaceutical composition for disrupting lactation in a mammary gland and for treating and preventing mastitis |
| US20050220801A1 (en) * | 2001-03-09 | 2005-10-06 | Hajime Otani | Immunopotentiators |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2725841C2 (ru) * | 2013-06-06 | 2020-07-06 | Сева Сантэ Анималь | Композиции и способ контроля инфекций у млекопитающих, не относящихся к человеку, с применением белков острой фазы |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006117784A2 (en) | 2006-11-09 |
| CL2011000039A1 (es) | 2011-06-10 |
| WO2006117784A3 (en) | 2009-05-22 |
| AU2006242842B2 (en) | 2011-12-08 |
| CA2607155A1 (en) | 2006-11-09 |
| ES2400511T3 (es) | 2013-04-10 |
| IN2014DN10391A (https=) | 2015-08-14 |
| KR20080012933A (ko) | 2008-02-12 |
| US7968513B2 (en) | 2011-06-28 |
| MX2007013866A (es) | 2008-04-07 |
| KR20130122979A (ko) | 2013-11-11 |
| EP1890720A2 (en) | 2008-02-27 |
| EP1890720A4 (en) | 2010-05-26 |
| BRPI0611301A2 (pt) | 2010-08-31 |
| US20110212886A1 (en) | 2011-09-01 |
| EP1890720B1 (en) | 2013-01-09 |
| CN106421749A (zh) | 2017-02-22 |
| CA2607155C (en) | 2016-09-13 |
| AR059462A1 (es) | 2008-04-09 |
| JP2008540399A (ja) | 2008-11-20 |
| JP5247429B2 (ja) | 2013-07-24 |
| EA200702401A1 (ru) | 2008-08-29 |
| AU2006242842A1 (en) | 2006-11-09 |
| US8338363B2 (en) | 2012-12-25 |
| PL1890720T3 (pl) | 2013-06-28 |
| KR101340676B1 (ko) | 2013-12-18 |
| US20090069218A1 (en) | 2009-03-12 |
| UY29515A1 (es) | 2007-11-30 |
| NZ563936A (en) | 2010-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8338363B2 (en) | Pharmaceutical compositions comprising casein derived peptides and methods of use thereof | |
| ES2249207T3 (es) | Agente de supresion de la resorcion osea. | |
| US20090305947A1 (en) | Livestock management for improved reproductive efficiency | |
| JP2008540399A5 (https=) | ||
| EP2828281B1 (en) | Peptides for management of lactation | |
| US20240207352A1 (en) | Compositions and methods for modulating mammary disorders and conditions | |
| JP2009173558A (ja) | 抗イヌ歯周病組成物 | |
| CN101247721B (zh) | 包括酪蛋白衍生肽的药物组合物及其使用方法 | |
| AU2012200889B2 (en) | Pharmaceutical compositions comprising casein derived peptides and methods of use thereof | |
| HK1120368A (en) | Pharmaceutical compositions comprising casein derived peptides and methods of use thereof | |
| IL222487A (en) | Casein-derived peptides and methods for using them to increase milk yield | |
| IL222486A (en) | Casein-derived peptides and methods for using them to enhance milk cleanliness | |
| IL187120A (en) | Casein-derived peptides and methods for their use in the herd's interface with milk | |
| JP2025537820A (ja) | 乳房の障害および状態を調節するための組成物および方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |